Clinical Trials Search Results

  • Resize font
  • Print
  • Email
  • Facebook
  • Twitter
  • Google+
  • Pinterest

Initial search results include only NCI-sponsored clinical trials. To search all trials, click the "REFINE SEARCH" button, scroll down to the Trial ID/Sponsor section and select the "All" check box in the Sponsor of Trial section.

View Content for:
Display:
?
Drug:  semaxanib
Find trials that include:  Any drugs shown
Trial Status:  Closed
Results 1-25 of 26 for your search:
Start Over
Leucovorin and Fluorouracil With or Without SU5416 in Treating Patients With Metastatic Colorectal Cancer
Phase: Phase III
Type: Treatment
Status: Completed
Age: 18 and over
Sponsor: Pharmaceutical / Industry
Protocol IDs: SUGEN-SU5416.031, CDR0000067499, UCLA-9909008, NCT00004252
Phase I/II Study of SU5416 with Fluorouracil and Leucovorin Calcium in Patients with Metastatic Colorectal Cancer (Summary Last Modified 01/2000)
Phase: Phase II, Phase I
Type: Treatment
Status: Closed
Age: Over 18
Sponsor: NCI, Pharmaceutical / Industry
Protocol IDs: UCLA-9901075, SUGEN-SU5416.010, NCI-G99-1546
SU5416 in Treating Patients With Recurrent Astrocytoma or Mixed Glioma That Has Not Responded to Radiation Therapy
Phase: Phase II, Phase I
Type: Biomarker/Laboratory analysis, Treatment
Status: Completed
Age: 18 and over
Sponsor: NCI, Other
Protocol IDs: CDR0000067527, NABTC-9902, MSKCC-01045, NCI-00-C-0173, NCT00004868
Liposomal Daunorubicin and SU5416 in Treating Patients With Hematologic Cancer That Has Not Responded to Initial Therapy
Phase: Phase II, Phase I
Type: Biomarker/Laboratory analysis, Treatment
Status: Completed
Age: 18 and over
Sponsor: NCI
Protocol IDs: NCI-2012-02329, ID99-341, CDR0000067822, MDA-ID-99341, NCI-673, 673, NCT00005942
SU5416 and Irinotecan in Treating Patients With Advanced Colorectal Cancer
Phase: Phase II, Phase I
Type: Biomarker/Laboratory analysis, Treatment
Status: Completed
Age: 18 and over
Sponsor: NCI
Protocol IDs: NCI-2012-02330, ID-99-243, N01CM17003, CDR0000067823, MDA-ID-99243, NCI-88, 88, NCT00005818
Phase I/II Randomized Study of Neoadjuvant Radiotherapy With or Without SU5416 in Patients With Stage IB or IIA Soft Tissue Sarcoma
Phase: Phase II, Phase I
Type: Treatment
Status: Completed
Age: 18 and over
Sponsor: NCI
Protocol IDs: RTOG-S-0120, NCT00023725
SU5416 in Treating Patients With AIDS-Related Kaposi's Sarcoma
Phase: Phase II
Type: Biomarker/Laboratory analysis, Treatment
Status: Completed
Age: 18 and over
Sponsor: NCI, Other
Protocol IDs: AMC-022, CDR0000067633, NCT00005042
SU5416 in Treating Patients With Advanced, Metastatic, or Recurrent Soft Tissue Sarcomas
Phase: Phase II
Type: Treatment
Status: Completed
Age: 18 and over
Sponsor: NCI
Protocol IDs: CDR0000067893, DFCI-00002, NCI-330, 330, NCT00005862
SU5416 Compared to Dexamethasone in Treating Patients With Progressive Prostate Cancer That Has Not Responded to Hormone Therapy
Phase: Phase II
Type: Treatment
Status: Completed
Age: 18 and over
Sponsor: NCI, Other
Protocol IDs: 10428, UCCRC-10428, UCCRC-NCI-49, NCI-49, 49, NCT00006002
SU5416 in Treating Patients With Refractory or Relapsed Multiple Myeloma
Phase: Phase II
Type: Treatment
Status: Completed
Age: 18 and over
Sponsor: NCI, Other
Protocol IDs: FCCC-00009, CDR0000068022, NCI-58, 58, NCT00006013
SU5416 in Treating Patients With Malignant Mesothelioma
Phase: Phase II
Type: Treatment
Status: Completed
Age: 18 and over
Sponsor: NCI
Protocol IDs: NCI-2012-02351, UCCRC-10409, UCCRC-NCI-44, NCI-44, CDR0000068023, 44, NCT00006014
Phase II Study of SU5416 in Patients With Advanced or Recurrent Squamous Cell Carcinoma of the Head and Neck
Phase: Phase II
Type: Treatment
Status: Completed
Age: 18 and over
Sponsor: NCI
Protocol IDs: MSKCC-00049, NCI-79, NCT00006361, 79
SU5416 and Interferon Alfa-2b in Treating Patients With Unresectable or Metastatic Kidney Cancer
Phase: Phase II
Type: Treatment
Status: Completed
Age: 18 and over
Sponsor: NCI, Other
Protocol IDs: 00041, U01CA062505, P30CA033572, CHNMC-PHII-23, NCI-T99-0085, CDR0000068262, T99-0085, NCT00006384
Thalidomide and SU5416 in Treating Patients With Metastatic Melanoma
Phase: Phase II
Type: Biomarker/Laboratory analysis, Treatment
Status: Completed
Age: 18 and over
Sponsor: NCI
Protocol IDs: CDR0000068677, UTHSC-IDD-99-27, SACI-IDD-99-27, NCI-66, 66, NCT00017316
Phase II Study of SU5416 in Patients With Persistent or Recurrent Cervical Squamous Cell Carcinoma
Phase: Phase II
Type: Treatment
Status: Completed
Age: Not specified
Sponsor: NCI
Protocol IDs: GOG-0227B, NCT00026260
SU5416 in Treating Patients With AIDS-Related Kaposi's Sarcoma
Phase: Phase I
Type: Treatment
Status: Completed
Age: 18 and over
Sponsor: Pharmaceutical / Industry
Protocol IDs: SUGEN-SU5416.003, CDR0000066829, LAC-USC-17K981, NCT00003720
SU5416 in Treating Patients With Advanced Solid Tumors
Phase: Phase I
Type: Treatment
Status: Completed
Age: 18 and over
Sponsor: NCI, Other
Protocol IDs: CWRU2Y99, U01CA062502, P30CA043703, NCI-T99-0095, T99-0095, NCT00005642
SU5416 and Doxorubicin in Treating Patients With Stage IIIB or Stage IV Inflammatory Breast Cancer
Phase: Phase I
Type: Biomarker/Laboratory analysis, Treatment
Status: Completed
Age: 18 and over
Sponsor: NCI, Other
Protocol IDs: CWRU5199, U01CA062502, P30CA043703, NCI-T99-0099, T99-0099, NCT00005822
SU5416 and Paclitaxel in Treating Patients With Recurrent, Locally Advanced or Metastatic Cancer of the Head and Neck
Phase: Phase I
Type: Biomarker/Laboratory analysis, Treatment
Status: Completed
Age: 18 and over
Sponsor: NCI, Other
Protocol IDs: CWRU1399, U01CA062502, P30CA043703, NCI-T99-0084, T99-0084, NCT00005647
Phase I Study of SU5416 With Irinotecan and Cisplatin in Patients With Advanced Solid Tumors (Summary Last Modified 01/2002)
Phase: Phase I
Type: Treatment
Status: Completed
Age: Over 18
Sponsor: NCI
Protocol IDs: OSU-00H0033, NCI-47, NCT00006000, 47
SU5416 and Paclitaxel in Treating Patients With Advanced Cancer
Phase: Phase I
Type: Biomarker/Laboratory analysis, Treatment
Status: Completed
Age: 18 and over
Sponsor: NCI, Other
Protocol IDs: CDR0000068191, U01CA062505, P30CA033572, CHNMC-PHI-30, CHNMC-IRB-99098, NCI-T99-0086, T99-0086, NCT00006257
Phase I Study of SU5416 and Carboplatin in Patients With Ovarian Epithelial, Fallopian Tube, or Primary Peritoneal Cancer That is Refractory to Prior Platinum
Phase: Phase I
Type: Treatment
Status: Completed
Age: 18 and over
Sponsor: NCI
Protocol IDs: NCI-00-C-0197, NCI-212, 212
Start Over